Sofregen picks up silk-based surgical scaffold from Allergan

dealmaking

Sofregen Medical, which is developing silk-based tech for soft tissue repair, acquired a silk-based surgical mesh from Allergan for an undisclosed amount. It will be Sofregen’s first product on the market.

The Seri surgical scaffold is a silk-derived bioprotein, which distinguishes it from other scaffolds derived from human cadaver or animal tissue. It is used for soft tissue support in cosmetic and reconstructive surgery and has been used in more than 10,000 procedures that require surgical mesh, Sofregen said in a statement.

The mesh is manufactured by twisting raw silk protein filaments into a multifilament fiber. Sericin, the gum that coats silk fiber, is then removed, leaving a silk protein filament that is constructed into a three-dimensional scaffold.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Founded in 2014 around technology developed at Tufts University, Sofregen aims to create products from silk biomaterial for medical and cosmetic procedures, such as scar repair, breast reconstruction and vocal cord augmentation. It has novel, injectable, silk-based products in its pipeline, according to the statement. In September, the company picked up $6.2 million in Series A funding.

“Silk has proven to promote regeneration of the body’s own tissue, allowing for tremendous potential to effectively repair both disfiguring injuries and delicate defects,” said Sofregen Chairman Howard Weisman, in the statement. “The global market for products to address soft-tissue aesthetics is estimated to reach $5 billion next year. We are excited to be adding the SERI product line to our platform, and look forward to continuing to help surgeons who are eager to restore confidence and improve the quality of life for patients around the world.”

Suggested Articles

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.

Since launching Grail into the world in 2016, Illumina has watched the cancer blood test developer grow into a multibillion-dollar startup enterprise.